Member Info for Supermobileman

Flash212,

Did you went to your mummy and daddy Pokerchips, Dallo and Nolupus to argue for you?

Its obvious The word "latter" is confusing lots of us here. I must admit the wording of the RNS is ambiguous. The way I see it is, the two conditions the significant deal and the 3 years from date of issue are connected. They are conjoined together and cannot be separated. The grant of share options can only be vested after 3 years which is the latter, but only if the significant deal is done with it.

Wigwammer,

Well said.

There is a sentence which say " The Remuneration Committee will determine when these conditions have been met".

It doesn't say "when one of these conditions have been met", but "when these conditions have been met". That imply to me both the significant deal completed and after 3 years have been met.

Flash212

You are a dumb a..

The RNS looks clear to me.

A significant deal must be completed between now and the next 3 years AND only then after 3 years can the grant of share options be vested.

If no significant deal signed and completed within 3 years from now, the grant of share options cannot be vested after 3 years.

But that don't mean it won't be vested at all. They could do a significant deal in, let say 5 years time as long as a significant deal is done and only after 3 years from now, can the grant of share options can be vested. They got 10 years to do it in from now.

Plain simple to me.

Funny when Nolupus said "I haven't been reading the other board for quite a while, but nobbygnome was only one of a very few worth reading on there".

Nolupus would say that because its Nolupus' own posts !

Lordloadsoflolly.

Nolupus on this board is nobbygnome on the ADVFN board, if you dont already know. Make no mistake they're are the same person.

IMM have not gone against FDA's recommendation. There's no evidence they did. Going straight into Phase 3 will still incorporate all of FDA's protocol as it were in Phase 2/3 adaptive study.

In a nutshell, in phase 2/3 they will stop briefly after 'phase 2' , report it, before moving onto 'phase 3'.

in Phase 3, they will do it in one go, no need of time delaying stoppages, therefore it will be quicker.

I will forecast the RNS will say,

"Don't panic Mr. Mainwaring"

If its bad, then you can kick the cat, throw your missus out of the house, headbutt your mother-in-law, rob a bank and smoke some weed. Otherwise stay calm.

There's a saying, 'keep your head when others are losing theirs'

Nolupus,

You should take a look at yourself in the mirror.

It is you who is trying to be too smart and too clever clogs.

The only thing brewing in Tim's office is the kettle. He reading his newspapers at the moment.

No on a serious note, let be honest with ourselves, we all know where this going contrary what some of us on here are saying. It just the time consuming delay getting there.

Where in the law constitutes a licensee must buy shares from the licensor?

How many do you know in the licencing pharma world have this happened.

What Alora done when they bought IMM's shares was a goodwill token gesture. A show of support.

Just what is Alora business, drug development or financial investment?

£663,000 left as of 31 December 2022, cash burn around £2m a year as you said lambo then IMM must be literally skint right now!

It is highly unusual in the pharma industry to fund raise when your down to your last penny or even totally skint! Fund raise are done many months in advance. So why haven't IMM already done so? What are they waiting for?

Come on lambo stop pretending you don't know. I expect IMM and the potential partner(s) for the CIDP indication for instance, are waiting for confirmation of the awarding of Orphan Drug Status as this will determine the CIDP value and subsequent licensing deal and with it the forthcoming upfront cash payment coming through IMM's letterbox.

It does not need to be the CIDP deal. It could be Lupuzor rest of the world deal or a deal on one of their anti-infectives. Any deal with cash payment will do it.

Now I posted this, IMM probably will shortly announce fund raise RNS!

.

Subcutaneous Injection was used in their original first phase 3 trial and all their previous trials.

Not long ago they had a RNS out stating the second future phase 3 would now be done by intravenous injection.

In the latest RNS, it now seems they revert it back to subcutaneous injection. They can't make their mind up.

If they succeed in their phase 3 trial Lupuzor will again have substantial price advantage over the competitors.

Avion's $25m more than enough covers the P2/P3 trial. There's no need for additional fund.

What is it you don't understand Nolupus?

(Sorry continuation from previous post)

But if the new adaptive phase 2/3 succeed and approved, Lupuzor will still have advantage over GSK and Astrazeneca if it has significant efficacy and no serious or none at all side effects.

I believed the chance of possiblity is high that it will succeed but nothing is guaranteed.

Reading on the last RNS update, it said the forth coming adaptive study will now be done by intravenous injection than by subcutaneous injection as it was in the previous phase 3 study.
Just wondering, if the previous phase 3 study was done by intravenous injection on the same lower dose that was used, as this method can get to the bloodstream more quickly, than we would probably have got significant efficacy and the endpoints required than we wouldn't be where we are now. The lower dose worked but probably should have been done by intravenous injection. Just a thought. That will be another argument.

For sure now, Lupuzor have lost its price advantage over the ones that are on the market. I can see the reason it was done by subcutaneous. It can be done by self injection by patients. This would cut out the fees charged by ' middle man ' the doctors, nurses. etc.

But if it is approved,

Nolupus

Blimey what a persistent pensioner. Just bow down gracefully and admit defeat.
No! wait, you're won! Hopefully this will shut him up. If you go to the kindergarten tomorrow, a kid will give you your gold medal around your neck.
Now can I get some sleep.

Nolupus

Whoever said Avion weren't satisfied with the data. Avion themselves?
Then why on earth did they first signed the licencing deal to fund phase 3 with $25m if they weren't satisfied with the data.
The recommendation came afterwards. It's now up to IMM/Avion whether to proceed or not. For the better or for the worse. We shall see.
The kindergarten opening tomorrow. Now make your way there.
I'm off to bed.

NolupusFFS, your so argumentative and sometimes full of crap. Always asking questions but never gives straight answers on this board. This is going round in circle. Go to a kindergarten they'll understand you.As you are retired, you live on this board. I don't. I got work to go to tomorrow.